Nykode Therapeutics AS (OSL:NYKD)

Market Cap	969.84M +14.7%
Revenue (ttm)	4.57M -95.1%
Net Income	-123.39M
EPS	-0.40
Shares Out	326.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	1.00 (33.67%)
Ex-Dividend Date	n/a

Volume	1,440,098
Average Volume	1,336,829
Open	3.160
Previous Close	3.140
Day's Range	2.968 - 3.160
52-Week Range	1.440 - 4.100
Beta	1.17
RSI	43.24
Earnings Date	Feb 25, 2026

About Nykode Therapeutics AS

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 59
• Stock Exchange: Oslo Børs
• Ticker Symbol: NYKD

Financial Performance

In 2025, Nykode Therapeutics AS's revenue was $453,000, a decrease of -95.05% compared to the previous year's $9.16 million. Losses were -$12.24 million, -68.47% less than in 2024.

Financial numbers in USD